PDK1 is relevant in a variety of clinical conditions throughout the body. As PDK1 regulates the PDH complex, it has been proven to be an important regulator in certain cells, including the beta cells within the islets of the pancreas. In order to optimize glucose-stimulated
insulin secretion (GSIS), a primary function of the pancreas, a low PDK1 activity must be maintained to keep PDH in a dephosphorylated and active state. Maintaining low PDK1 levels has also proven to be beneficial in certain regions of the brain, as it confers a high tolerance to
amyloid beta, a metabolite that is directly correlated with the development of
Alzheimer's disease.
Cancer The ubiquitous role of this gene lends itself to being involved in a variety of disease pathologies, including cancer. PDK1
mRNA expression is significantly associated with tumor progression; in fact, the presence of PDK1 can serve as a prognostic marker, indicating the level of success a patient can achieve. Specifically, this may serve as a biomarker in patients with
gastric cancer. In coordination, the inhibitor dichloroacetic acid may be used in the future as a treatment option for patients with this type of cancer. PDK1, as it regulates
hypoxia and
lactate production, is associated with a poor outcome in patients with
head and neck cancer. The buildup of glycolytic metabolites may promote
Hypoxia-Inducing Factor (HIF) activation, which creates a
feed-forward loop for malignancy progression. As such, using HIF-1 as a metabolite to regulate PDK1 is seen as another potential therapy, either on its own or in tandem with other therapies, for this type of cancer. In a further developed study, combined PDK1 and
CHK1 inhibition was shown to be required to kill
glioblastoma stem-like cells
in vitro and
in vivo. == References ==